Corvus Pharmaceuticals Inc.
CRVS
NSD
Sector: Healthcare
Industry: Biotechnology
0.76
USD
0.05
(7.32%)
Optionable: Yes Market Cap: 33 M 90-day average vol: 288,131
Previous close: 0.7073 Open: 0.695 Bid: 0.77 Ask: 0.77
52 week range
0.70 7.11
Last updated: Thursday 29th September 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 0.49 |
PE Ratio (TTM) | -1.10 |
Book Value per Share ($) | 1.73 |
5 Year PE Range | -17.6 , -2.3 |
Returns
7 Day Return | -4.01% | |
1 Month Return | -22.55% | |
3 Month Return | -23.33% | |
1 Year Return | -88.98% | |
3 Year Return | -74.78% | |
5 Year Return | -95.24% | |
YTD Return | -68.50% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 36.04 |
14 Day SMA ($) | 0.85 |
14 Day EMA ($) | 0.82 |
Money Flow Index | 22.65 |
Average True Range | 0.07 |
50 Day SMA ($) | 0.94 |
200 Day SMA ($) | 1.43 |
ADX | 34.38 |
MACD | -0.07 |
Growth
Free Cash Flow QoQ Growth | -4.62% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
CRVS Income Statement
Annual
| Invalid date | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of sales | 0 | -107000 | -1 M | -647000 | -239000 | -99000 | -786000 | -699000 | |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 123000 | 2 M | 8 M | 10 M | 11 M | 11 M | 12 M | 10 M | |
| Research & development expense | 38000 | 11 M | 29 M | 46 M | 39 M | 38 M | 32 M | 29 M | |
| Operating income | -161000 | -14 M | -37 M | -57 M | -49 M | -49 M | -44 M | -39 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other income net | 0 | -18 M | 0 | 0 | 0 | 0 | 37 M | -5 M | |
| Pre-tax Income (EBT) | -161000 | -31 M | -36 M | -56 M | -47 M | -47 M | -6 M | -43 M | |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income from total operations | -161000 | -31 M | -36 M | -56 M | -47 M | -47 M | -6 M | -43 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -161000 | -31 M | -36 M | -56 M | -47 M | -47 M | -6 M | -43 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -161000 | -31 M | -36 M | -56 M | -47 M | -47 M | -6 M | -43 M | |
| Depreciation | 0 | 107000 | 1 M | 647000 | 239000 | 99000 | 786000 | 699000 | |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -161000 | -14 M | -36 M | -56 M | -48 M | -48 M | -43 M | -43 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.02 | -1.54 | -2.36 | -2.72 | -1.71 | -1.59 | -0.2 | -1.03 | |
| Diluted EPS total | -0.02 | -1.54 | -2.36 | -2.72 | -1.71 | -1.59 | -0.2 | -1.03 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today